Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
1. Arcutis submitted a sNDA to expand ZORYVE for children aged 2+. 2. ZORYVE could be the first pediatric PDE4 inhibitor for plaque psoriasis. 3. Significant unmet need exists for approved pediatric psoriasis treatments. 4. Long-term studies show ZORYVE's safety and efficacy in young children. 5. The cream is steroid-free and well-tolerated on sensitive skin areas.